Saint Petersburg, FL, Nov. 06, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Apotheca Biosciences (OTC PINK: PCFP), a developer of cutting-edge medical products, nutraceuticals, drug formulations and cannabis delivery technologies for the healthcare and consumer care industry, is pleased to announce the intent to purchase Nano Creaciones S.A. P.I. de D.V. Research LLC (“Nano”). Nano currently holds several patents and patents pending for the treatment of certain medical conditions, and Apotheca Biosciences is thrilled to be able to leverage their existing technology for the development of next generation CBD-based OTC formulations.
Nano is on the cutting-edge of nanotechnology through their development of a cotton fiber gauze with silver nitrate nanoparticles that allow the users to discard any risk of wound infection while accelerating their tissue regeneration process. Currently, Nano is in the process of testing and fielding such medications for regulatory approval, studies, marketing, production and sales. Nano’s product has been tested in all aspects from the development and active duration of the “nanoparticles” to the “packaging” of the gauze and its density to allow its proper sterilization without damaging the product.
Nano has fully developed gauze, band-aids and sprays, while developing a line of the same products to include using CBD as a palliative. The Nano Gauze is made from pure silver nanoparticles, which are carefully dispersed in cotton fibers that are subjected to a meticulous sterilization process with the most advanced technology for contact with wounds and human tissues without compromising the action of the silver nanostructures. Apotheca Biosciences believes that using Nano’s products to deliver CBD as a palliative will bring the utmost quality and precise dosing to the consumer market. “We’ve gone through quality planning and development of our CBD blends and believe that using Nano’s products will be the perfect method of delivery for the healthcare and consumer markets,” said Sam Talari, Chief Executive Officer at Apotheca Biosciences.
Apotheca Biosciences is at the forefront of medical technologies with the development of a CBD pain patch for the healthcare and consumer care industry. This acquisition will provide knowledge and expertise to the development of this CBD product, along with our other products. Our pipeline of products includes transdermal, sublingual, and nasal delivery technologies for precise and controlled dosing of cannabinoids.
Apotheca Biosciences is a pioneering biotech company with an emphasis in research and development in addition to the creation of high-grade nutraceuticals and cosmetics. The health of our customers takes precedence and our solid business strategy ensures focus on customer well-being. Our goal is to lay the groundwork and continue research of cannabinoid receptiveness in patients and create nutraceuticals that reflects our strategy and research. For more information on Apotheca Biosciences, please visit www.apothecabio.com
About Apotheca Biosciences Inc.
Apotheca is a developer of cutting-edge medical products, nutraceuticals, formulation and delivery technologies for the healthcare and consumer care industry. Its pipeline of products includes, transdermal, sublingual, and nasal delivery technologies for precise and controlled dosing of cannabinoids. Apotheca believes that it can deliver meaningful benefits using its technologies to the world’s aging population. To request further information about Apotheca, please email info@apothecabio.com, or visit its website at http://www.apothecabio.com/, or visit it on FB @apotheca and Twitter @apotheca
Forward-Looking Statements
This press release may contain forward-looking statements covered within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to, among other things, plans and timing for the introduction or enhancement of our services and products, statements about future market conditions, supply and demand conditions, and other expectations, intentions and plans contained in this press release that are not historical fact and involve risks and uncertainties. Our expectations regarding future revenues depend upon our ability to develop and supply products and services that we may not produce today and that meet defined specifications. When used in this press release, the words "plan," "expect," "believe," and similar expressions generally identify forward-looking statements. These statements reflect our current expectations. They are subject to a number of risks and uncertainties, including, but not limited to, changes in technology and changes in pervasive markets. This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions.